Johnson & Johnson buy gerihouse
Zusammenfassung
Diese Einschätzung wurde am 25.03.15 mit einem Endkurs von 92,91 € beendet. Leichte Gewinne von 6,68 % verzeichnete die BUY Einschätzung von gerihouse. gerihouse hat 50% Zuversicht bei dieser EinschätzungJohnson Johnson ist ein international tätiges Unternehmen aus den USA, das in der Gesundheitsbranche tätig ist. Das Unternehmen bietet eine breite Palette an Produkten und Dienstleistungen an, darunter Pharmazeutika, Medizinprodukte und Konsumgüter wie Mundpflege- und Hautpflegeprodukte. Johnson Johnson ist an der New Yorker Börse gelistet (Symbol JNJ) und hat eine Marktkapitalisierung von mehr als 450 Milliarden US-Dollar. Die Aktie gilt als eine der Blue-Chip-Aktien und ist aufgrund ihrer stabilen Geschäftsentwicklung und Dividendenrendite bei vielen Anlegern beliebt.
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Johnson & Johnson | -2,96 % | -2,96 % | -10,46 % | 0,16 % |
| iShares Core DAX® | -1,78 % | -1,25 % | 11,66 % | 12,71 % |
| iShares Nasdaq 100 | -2,15 % | 0,30 % | 37,53 % | 41,65 % |
| iShares Nikkei 225® | -4,03 % | -3,75 % | 17,14 % | 0,39 % |
| iShares S&P 500 | -1,97 % | 0,31 % | 25,62 % | 40,08 % |
Kommentare von gerihouse zu dieser Einschätzung
In der Diskussion Johnson & Johnson diskutieren
Sicher
Johnson&Johnson wieder attraktiv.
Jefferies Group reissued their hold rating on shares of Johnson & Johnson (NYSE:JNJ) in a research report sent to investors on Thursday morning. The firm currently has a $114.00 price target on the stock, up from their previous price target of $110.00.
JNJ has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a neutral rating on shares of Johnson & Johnson in a research note on Friday, November 28th. They now have a $113.00 price target on the stock. Separately, analysts at Bank of America reiterated a neutral rating on shares of Johnson & Johnson in a research note on Wednesday, October 15th. They now have a $99.00 price target on the stock, down previously from $106.00. Twelve equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $104.19.
Johnson & Johnson traded up 0.31% during mid-day trading on Thursday, hitting $108.85. 1,220,847 shares of the company’s stock traded hands. Johnson & Johnson has a 52 week low of $86.09 and a 52 week high of $109.49. The stock’s 50-day moving average is $106.6 and its 200-day moving average is $104.0. The company has a market cap of $304.7 billion and a price-to-earnings ratio of 17.97. Johnson & Johnson also was the target of unusually large options trading activity on Friday. Stock investors bought 33,559 call options on the stock. This represents an increase of 241% compared to the average daily volume of 9,831 call options.
Johnson & Johnson last announced its earnings results on Tuesday, October 14th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.43 by $0.07. The company had revenue of $18.50 billion for the quarter, compared to the consensus estimate of $18.41 billion. During the same quarter in the previous year, the company posted $1.36 earnings per share. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post $5.96 earnings per share for the current fiscal year.
Beendete Einschätzungen von gerihouse zu Johnson & Johnson
Johnson & Johnson
05.08.22
05.08.23
06.08.23
Johnson & Johnson
08.07.21
08.07.22
08.07.22
Johnson & Johnson
09.09.20
04.11.21
12.02.21
Johnson & Johnson
28.08.19
14.04.20
14.04.20
Johnson & Johnson
18.07.17
08.12.17
08.12.17
Johnson & Johnson
19.04.17
26.06.17
26.06.17
Johnson & Johnson
21.09.15
01.12.15
01.12.15